Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

BACKGROUND: Ipilimumab and Nivolumab, targeting the molecules CTLA-4, PD-1, respectively,have shown efficacy against several types of cancer. Despite these results, only a small percentage of patients maintains a long-lasting effect. Even Ipilimumab, in combination with nivolumab, has demonstrated a...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchetti, Paolo, Botticelli, Andrea, Ascierto, Antonio Paolo, Curigliano, Giuseppe, Giannarelli, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688006/
https://www.ncbi.nlm.nih.gov/pubmed/33239030
http://dx.doi.org/10.1186/s12967-020-02588-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688006/
https://www.ncbi.nlm.nih.gov/pubmed/33239030
http://dx.doi.org/10.1186/s12967-020-02588-2

Ejemplares similares